There's not a whole load of detail, but we know we are talking about huge cohorts: 10k adult and 2k child cohorts, plus controls (which are likely to exist already for most of the omics, as we are late to this party). There's nothing like this anywhere in the world.
Plus a lot of new researchers are coming to play. Profs Paul Moss (infection), Maria Fitzgerald (pain), Jim Horne (sleep) and Paul Little have certainly shown an interest before but I'm not sure they've done any mecfs-specific research. Profs Chris Ponting, Colin Smith and George Davey Smith (Genomics, which increasingly includes transcriptomics (RNA) and a load of other stuff); Dr Rick Dunn (metabolomics), Prof Caroline Relton (Epigenetics), Somalogic (proteomics/serologics) are all new AFAIK.
[
SomaLogic | Unlocking protein biomarkers to transform healthcare]
My main take out from this is that a whole load of talent from other areas is taking a keen interest in mecfs for the first time, ready to apply some smart technology - widely used in other, less-neglected illnesses - to our illness. And doing so on a huge sample. Finally, some serious, large-scale biomedical research in the UK (though this would also be the biggest cohort by far anywhere in the world).
It's not going to be fast though, sadly. Big science isn't quick.
And this
Good! The NIH showed how essential it is that this is done well. Apart from better relations, proper patient involvement makes for better science, in my view.